These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 38530204)

  • 61. Elexacaftor, tezacaftor and ivacaftor: a case of severe rash and approach to desensitisation.
    Cheng A; Baker O; Hill U
    BMJ Case Rep; 2022 Mar; 15(3):. PubMed ID: 35236685
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor Therapy in Three Subjects with the Cystic Fibrosis Genotype Phe508del/Unknown and Advanced Lung Disease.
    Terlizzi V; Colangelo C; Marsicovetere G; D'Andria M; Francalanci M; Innocenti D; Masi E; Avarello A; Taccetti G; Amato F; Comegna M; Castaldo G; Salvatore D
    Genes (Basel); 2021 Jul; 12(8):. PubMed ID: 34440351
    [TBL] [Abstract][Full Text] [Related]  

  • 63. CFTR Modulators: Current Status and Evolving Knowledge.
    Regard L; Martin C; Da Silva J; Burgel PR
    Semin Respir Crit Care Med; 2023 Apr; 44(2):186-195. PubMed ID: 36535667
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Rescue of chloride and bicarbonate transport by elexacaftor-ivacaftor-tezacaftor in organoid-derived CF intestinal and cholangiocyte monolayers.
    Bijvelds MJC; Roos FJM; Meijsen KF; Roest HP; Verstegen MMA; Janssens HM; van der Laan LJW; de Jonge HR
    J Cyst Fibros; 2022 May; 21(3):537-543. PubMed ID: 34922851
    [TBL] [Abstract][Full Text] [Related]  

  • 65. A Review of Trikafta: Triple Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulator Therapy.
    Zaher A; ElSaygh J; Elsori D; ElSaygh H; Sanni A
    Cureus; 2021 Jul; 13(7):e16144. PubMed ID: 34268058
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Modulator Therapy in Cystic Fibrosis Patients with
    Terlizzi V; Centrone C; Ferrari B; Castellani C; Gunawardena TNA; Taccetti G; Laselva O
    J Pers Med; 2022 Aug; 12(9):. PubMed ID: 36143206
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Concomitant Use of Elexacaftor/Tezacaftor/Ivacaftor and Etanercept in a Cystic Fibrosis Patient with Juvenile Idiopathic Arthritis.
    Orsini SI; Marrani E; Pagnini I; Taccetti G; Terlizzi V; Simonini G
    J Clin Med; 2023 Feb; 12(5):. PubMed ID: 36902517
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Elexacaftor-Tezacaftor-Ivacaftor Therapy for Chronic Sinus Disease in Cystic Fibrosis.
    Sheikh S; Ho ML; Eisner M; Gushue C; Paul G; Holtzlander M; Johnson T; McCoy KS; Lind M
    JAMA Otolaryngol Head Neck Surg; 2023 Dec; 149(12):1075-1082. PubMed ID: 37676668
    [TBL] [Abstract][Full Text] [Related]  

  • 69. CFTR modulator therapy alters plasma sphingolipid profiles in people with cystic fibrosis.
    Westhölter D; Schumacher F; Wülfinghoff N; Sutharsan S; Strassburg S; Kleuser B; Horn PA; Reuter S; Gulbins E; Taube C; Welsner M
    J Cyst Fibros; 2022 Jul; 21(4):713-720. PubMed ID: 35168870
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Biliary disease and cholecystectomy after initiation of elexacaftor/ivacaftor/tezacaftor in adults with cystic fibrosis.
    Safirstein J; Grant JJ; Clausen E; Savant D; Dezube R; Hong G
    J Cyst Fibros; 2021 May; 20(3):506-510. PubMed ID: 32736949
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Tezacaftor and ivacaftor for the treatment of cystic fibrosis.
    Paterson SL; Barry PJ; Horsley AR
    Expert Rev Respir Med; 2020 Jan; 14(1):15-30. PubMed ID: 31626570
    [No Abstract]   [Full Text] [Related]  

  • 72. Radiological and long-term clinical response to elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis with advanced lung disease.
    Aalbers BL; Mohamed Hoesein FAA; Hofland RW; Bronsveld I; Kruijswijk MA; Schotman S; Slingerland CW; Panhuis H; van der Ent CK; Heijerman HGM
    Pediatr Pulmonol; 2023 Aug; 58(8):2317-2322. PubMed ID: 37222401
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Use of CFTR modulators in special populations, part 3: Solid organ transplant.
    Kadouh NK; Elijah J; Fitzgerald LJ; Phan H
    Pediatr Pulmonol; 2023 Dec; 58(12):3393-3402. PubMed ID: 37067449
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Non-respiratory health-related quality of life in people with cystic fibrosis receiving elexacaftor/tezacaftor/ivacaftor.
    Fajac I; Daines C; Durieu I; Goralski JL; Heijerman H; Knoop C; Majoor C; Bruinsma BG; Moskowitz S; Prieto-Centurion V; Van Brunt K; Zhang Y; Quittner A
    J Cyst Fibros; 2023 Jan; 22(1):119-123. PubMed ID: 36114142
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Measuring the effect of elexacaftor/tezacaftor/ivacaftor combination therapy on the respiratory pump in people with CF using dynamic chest radiography.
    FitzMaurice TS; McCann C; Nazareth D; Shaw M; McNamara PS; Walshaw MJ
    J Cyst Fibros; 2022 Nov; 21(6):1036-1041. PubMed ID: 35101365
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Effect of highly effective modulator therapy on quality of life in adults with cystic fibrosis.
    DiMango E; Spielman DB; Overdevest J; Keating C; Francis SF; Dansky D; Gudis DA
    Int Forum Allergy Rhinol; 2021 Jan; 11(1):75-78. PubMed ID: 32985756
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Long-term tezacaftor/ivacaftor safety and efficacy in people with cystic fibrosis and an F508del-CFTR mutation: 96-week, open-label extension of the EXTEND trial.
    Flume PA; Harris RS; Paz-Diaz H; Ahluwalia N; Higgins M; Campbell D; Berhane I; Shih JL; Sawicki G
    J Cyst Fibros; 2023 May; 22(3):464-470. PubMed ID: 36581484
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Urticaria multiforme-like eruption due to a novel agent elexacaftor/tezacaftor/ivacaftor in a pediatric patient with cystic fibrosis.
    Goldberg RH; Matthews NH; Hristov AC; Wang F
    JAAD Case Rep; 2021 Dec; 18():71-73. PubMed ID: 34841028
    [No Abstract]   [Full Text] [Related]  

  • 79. Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapy: A Review for the Otolaryngologist.
    Lee SE; Farzal Z; Daniels MLA; Thorp BD; Zanation AM; Senior BA; Ebert CS; Kimple AJ
    Am J Rhinol Allergy; 2020 Jul; 34(4):573-580. PubMed ID: 32168995
    [TBL] [Abstract][Full Text] [Related]  

  • 80. From Ivacaftor to Triple Combination: A Systematic Review of Efficacy and Safety of CFTR Modulators in People with Cystic Fibrosis.
    Gramegna A; Contarini M; Aliberti S; Casciaro R; Blasi F; Castellani C
    Int J Mol Sci; 2020 Aug; 21(16):. PubMed ID: 32824306
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.